Cas no 104987-30-6 (Dihydro FK-506)

Dihydro FK-506 is a semi-synthetic derivative of the immunosuppressive macrolide FK-506 (Tacrolimus), featuring a reduced double bond in its structure. This modification enhances its stability and bioavailability while retaining potent calcineurin inhibition, which is critical for suppressing T-cell activation. The compound exhibits improved pharmacokinetic properties, including reduced metabolic degradation, making it a valuable candidate for research in transplantation and autoimmune therapies. Its mechanism of action involves binding to FKBP-12, forming a complex that inhibits phosphatase activity, thereby blocking IL-2 transcription. Dihydro FK-506 is primarily utilized in preclinical studies to explore optimized immunosuppressive regimens with potentially reduced side effects compared to its parent compound.
Dihydro FK-506 structure
Dihydro FK-506 structure
Product Name:Dihydro FK-506
CAS No:104987-30-6
MF:C44H71NO12
MW:806.034054994583
MDL:MFCD28987635
CID:94960
PubChem ID:13819087
Update Time:2025-05-20

Dihydro FK-506 Chemical and Physical Properties

Names and Identifiers

    • DIHYDRO-FK506
    • Dihydro FK-506
    • Dihydro Tacrolimus
    • Tsukubamycin B
    • CHEMBL347139
    • Dihydro-fk-506, (-)-
    • 0SDH06DWVW
    • Dihydro-FK-506
    • TACROLIMUS MONOHYDRATE IMPURITY E [EP IMPURITY]
    • Q27237196
    • UNII-0SDH06DWVW
    • 104987-30-6
    • (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-propyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
    • 1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-propyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetraone
    • FT-0666939
    • 1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-propyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene-2,3,10,16-tetraone
    • RQYGKZGKXDOUEO-UHFFFAOYSA-N
    • 1,14-dihydroxy-12-[2-(4-hydroxy-3methoxycyclohexyl)-1-methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-propyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene-2,3,10,16-tetraone
    • TACROLIMUS IMPURITY, TACROLIMUS 8-PROPYL ANALOG-(USP IMPURITY)
    • Tacrolimus impurity, tacrolimus 8-propyl analog-(USP)
    • TACROLIMUS MONOHYDRATE IMPURITY E (EP IMPURITY)
    • TACROLIMUS IMPURITY, TACROLIMUS 8-PROPYL ANALOG-[USP IMPURITY]
    • (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-((E)-1-((1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl)prop-1-en-2-yl)-23,25-dimethoxy-13,19,21,27-tetramethyl-17-propyl-11,28-dioxa-4-azatricyclo(22.3.1.04,9)octacos-18-ene-2,3,10,16-tetrone
    • Tacrolimus impurity, tacrolimus 8-propyl analog-[USP]
    • MDL： MFCD28987635
    • Inchi： 1S/C44H71NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h19,21,26,28-34,36-40,46-47,52H,10-18,20,22-24H2,1-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
    • InChI Key： RQYGKZGKXDOUEO-LFZNUXCKSA-N
    • SMILES： O1[C@]2(C(C(N3CCCC[C@H]3C(=O)O[C@H](/C(/C)=C/[C@@H]3CC[C@H]([C@@H](C3)OC)O)[C@H](C)[C@H](CC([C@H](CCC)C=C(C)C[C@H](C)C[C@@H]([C@@H]1[C@H](C[C@H]2C)OC)OC)=O)O)=O)=O)O |c:37|

Computed Properties

  • Exact Mass: 805.49800
  • Monoisotopic Mass: 805.49762670g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 3
  • Hydrogen Bond Acceptor Count: 12
  • Heavy Atom Count: 57
  • Rotatable Bond Count: 7
  • Complexity: 1450
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 14
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 2
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 3.1
  • Topological Polar Surface Area: 178?2

Experimental Properties

  • PSA: 178.36000
  • LogP: 4.80090

Dihydro FK-506 Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
D448950-1mg
Dihydro FK-506
 104987-30-6
1mg
 $ 131.00 2023-09-07
TRC
D448950-2.5mg
Dihydro FK-506
 104987-30-6
2.5mg
 $187.00 2023-05-18
TRC
D448950-5mg
Dihydro FK-506
 104987-30-6
5mg
 $351.00 2023-05-18
TRC
D448950-10mg
Dihydro FK-506
 104987-30-6
10mg
 $ 672.00 2023-09-07
TRC
D448950-25mg
Dihydro FK-506
 104987-30-6
25mg
 $ 1478.00 2023-09-07
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
1642835-15MG
Dihydro FK-506
 104987-30-6
15mg
 ￥13746.16 2024-12-30
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.
1642835-15MG
104987-30-6
15MG
 ￥18571.67 2023-01-05
eNovation Chemicals LLC
D701146-160mg
Dihydro Tacrolimus
 104987-30-6 95%
160mg
 $1395 2024-08-03
eNovation Chemicals LLC
D701146-185mg
Dihydro Tacrolimus
 104987-30-6 95%
185mg
 $1485 2024-08-03
SHENG KE LU SI SHENG WU JI SHU
sc-391955-2.5 mg
Tsukubamycin B,
 104987-30-6
2.5 mg
 ￥2,016.00 2023-07-10

Dihydro FK-506 Related Literature

Related Categories

Additional information on Dihydro FK-506

Comprehensive Guide to Dihydro FK-506 (CAS No. 104987-30-6): Properties, Applications, and Market Insights

Dihydro FK-506, with the CAS number 104987-30-6, is a derivative of the well-known immunosuppressant FK-506 (Tacrolimus). This compound has garnered significant attention in the fields of immunology and pharmacology due to its unique properties and potential therapeutic applications. Researchers and pharmaceutical companies are increasingly exploring its benefits, especially in the context of autoimmune diseases and organ transplantation.

The chemical structure of Dihydro FK-506 is characterized by a reduced form of the parent molecule, which may influence its biological activity and pharmacokinetics. This modification has been studied for its potential to enhance efficacy or reduce side effects compared to FK-506. The compound's mechanism of action involves binding to immunophilins, thereby inhibiting calcineurin and suppressing T-cell activation, a critical pathway in immune response modulation.

One of the most searched questions about Dihydro FK-506 is its comparison to FK-506. Users often inquire about the differences in potency, bioavailability, and clinical applications. Studies suggest that the dihydro form may offer improved stability or altered metabolic pathways, making it a subject of ongoing research. This aligns with the growing interest in immunosuppressive therapies and personalized medicine, which are trending topics in the pharmaceutical industry.

In terms of applications, Dihydro FK-506 is primarily investigated for its role in organ transplantation and autoimmune disorders. The demand for effective immunosuppressants with fewer side effects has driven research into derivatives like this one. Additionally, its potential use in dermatology (e.g., for treating psoriasis or atopic dermatitis) and ophthalmology (e.g., for managing uveitis) is being explored, addressing common patient concerns about long-term treatment safety.

The market for Dihydro FK-506 is evolving, with pharmaceutical companies investing in novel formulations and delivery systems. The rise of biologics and small-molecule drugs has created a competitive landscape, where compounds like this one are evaluated for their niche advantages. SEO trends indicate that users frequently search for "buy Dihydro FK-506" or "Dihydro FK-506 suppliers," reflecting commercial interest in the compound.

From a regulatory perspective, Dihydro FK-506 is not classified as a controlled substance or hazardous material, which simplifies its use in research and development. However, quality standards and sourcing remain critical, as highlighted by queries about "high-purity Dihydro FK-506" and "CAS 104987-30-6 specifications." Ensuring compliance with Good Manufacturing Practices (GMP) is essential for suppliers and end-users alike.

In summary, Dihydro FK-506 (CAS No. 104987-30-6) represents a promising area of research in immunomodulation. Its unique properties, coupled with the demand for safer immunosuppressants, position it as a compound of significant scientific and commercial interest. As studies progress, its applications may expand, offering new solutions for patients and healthcare providers.

104987-30-6 (Dihydro FK-506) Related Products

Recommended suppliers
Suzhou Genelee Bio-Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Suzhou Genelee Bio-Technology Co., Ltd.
Nanjing jingzhu bio-technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Nanjing jingzhu bio-technology Co., Ltd.
Enjia Trading Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Enjia Trading Co., Ltd
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.